Patent EP0139460A2 successfully refreshed from Google Patents.
EP0139460A2
Expired / Lapsed
EP
⏱️ 0.0 years remaining
Benzodiazepines and their therapeutic use
Assignee: Pharmacia and Upjohn Co
•
Filing: 1984-09-10
•
Granted: —
•
Expires: 2004-09-10
Abstract
Abstract For treating the negative symptoms of schizophrenia in humans, a benzodiazepine of the formula wherein X is H, CH 3 , CH 2 OH, alkoxymethyl, alkanoyloxymethyl or carboxyalkanoyloxymethyl, Y is H or OH and Z is H or Cl, is used.
Inventors
- 👤 Donald Richard Mahan
Bibliographic Details
Application Number
—
Jurisdiction
EP
Data Source
google_patents
Last Synchronized
2026-11-04 06:41
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/395; A61K31/55; A61P; A61P25/00; A61P25/18
Claims Analysis
Total Claims: 12
Claim 1
Independent Claim
108 words
A compound of Formula I when used to prevent or treat the negative symptoms of schizophrenia in humans: X is a member selected from the group consisting of -H, -CH 3 , and -CH 2 -0-R; wherein R is hydrogen, alkyl of from 1 to 3 carbon atoms, inclusive or wherein n is 0 to 16, inclusive, and m is 1 to 16, inclusive; Y is hydrogen or, provided when Z is hydrogen and X is CH 3 , hydroxy; Z is hydrogen or, provided when Y is hydrogen and X is -CH 3 , chloro; or the pharmacologically acceptable acid addition salt or a (5) N-oxide thereof.
Claim 2
Dependent Claim
108 words
A compound of Formula I when used to prevent or treat the negative symptoms of schizophrenia in humans: X is a member selected from the group consisting of -H, -CH 3 , and -CH 2 -0-R; wherein R is hydrogen, alkyl of from 1 to 3 carbon atoms, inclusive or wherein n is 0 to 16, inclusive, and m is 1 to 16, inclusive; Y is hydrogen or, provided when Z is hydrogen and X is CH 3 , hydroxy; Z is hydrogen or, provided when Y is hydrogen and X is -CH 3 , chloro; or the pharmacologically acceptable acid addition salt or a (5) N-oxide thereof.
Claim 3
Dependent Claim
24 words
8-chloro-1-hydroxymethyl-6-phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepine or its pharmacologically acceptable acid addition salts or its N-oxide when used to prevent or treat the negative symptoms of schizophrenia in humans.
Claim 4
Dependent Claim
24 words
8-chloro-1-hydroxymethyl-6-phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepine or its pharmacologically acceptable acid addition salts or its N-oxide when used to prevent or treat the negative symptoms of schizophrenia in humans.
Claim 5
Dependent Claim
24 words
8-chloro-6-phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepine or its pharmacologically acceptable acid addition salts or its N-oxide when used to prevent or treat the negative symptoms of schizophrenia in humans.
Claim 6
Dependent Claim
24 words
8-chloro-6-phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepine or its pharmacologically acceptable acid addition salts or its N-oxide when used to prevent or treat the negative symptoms of schizophrenia in humans.
Claim 7
Dependent Claim
24 words
1-methyl-8-chloro-6-phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepine or its pharmacologically acceptable acid addition salts or its N-oxide when used to prevent or treat the negative symptoms of schizophrenia in humans.
Claim 8
Dependent Claim
24 words
1-methyl-8-chloro-6-phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepine or its pharmacologically acceptable acid addition salts or its N-oxide when used to prevent or treat the negative symptoms of schizophrenia in humans.
Claim 9
Dependent Claim
24 words
1-methyl-4-hydroxy-8-chloro-6-phenyl-4H-s-triazolo[4,3-a][1,4]-benzodiazepine or its pharmacologically acceptable acid addition salts or its N-oxide when used to prevent or treat the negative symptoms of schizophrenia in humans.
Claim 10
Dependent Claim
24 words
1-methyl-4-hydroxy-8-chloro-6-phenyl-4H-s-triazolo[4,3-a][1,4]-benzodiazepine or its pharmacologically acceptable acid addition salts or its N-oxide when used to prevent or treat the negative symptoms of schizophrenia in humans.
Claim 11
Dependent Claim
24 words
1-methyl-8-chloro-6-(o-chlorophenyl)-4H-s-triazolo[4,3-a][1,4]-benzodiazepine or its pharmacologically acceptable acid addition salts or its N-oxide when used to prevent or treat the negative symptoms of schizophrenia in humans.
Claim 12
Dependent Claim
24 words
1-methyl-8-chloro-6-(o-chlorophenyl)-4H-s-triazolo[4,3-a][1,4]-benzodiazepine or its pharmacologically acceptable acid addition salts or its N-oxide when used to prevent or treat the negative symptoms of schizophrenia in humans.
References Cited (Backward Citations)
No citation records indexed.
USPTO Annuity & Maintenance Windows
Maintenance schedule is calculated for granted US utility patents.